Second- and third-generation ALK inhibitors for non-small cell lung cancer

被引：0
作者：
Jingjing Wu
John Savooji
Delong Liu
机构：
[1] The First Affiliated Hospital of Zhengzhou University,Department of Oncology
[2] Westchester Medical Center and New York Medical College,Department of Medicine
来源：
Journal of Hematology & Oncology | / 9卷
关键词：
Brain Metastasis; Pemetrexed; Anaplastic Lymphoma Kinase; Anaplastic Large Cell Lymphoma; Crizotinib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Crizotinib as the first-generation ALK inhibitor has shown significant activity in ALK-mutated non-small cell lung cancer (NSCLC). Second- and third-generation ALK inhibitors are entering clinical applications for ALK+ NSCLC. In addition, a third-generation ALK inhibitor, lorlatinib (PF-06463922), was reported to resensitize NSCLC to crizotinib. This review provided a summary of clinical development of alectinib, ceritinib, brigatinib (AP26113), and lorlatinib.
引用
收藏
相关论文
共 50 条
[41]   New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer [J].
Laird Cameron ;
Benjamin Solomon .
Current Treatment Options in Oncology, 2015, 16
[42]   Cystic brain metastases in ALK-rearranged non-small cell lung cancer [J].
Marta, Guilherme Nader ;
da Cunha Colombo Bonadio, Renata Rodrigues ;
Martins, Renata Eiras ;
Zuppani, Henrique Bortot ;
de Castro Junior, Gilberto .
ECANCERMEDICALSCIENCE, 2018, 12
[43]   Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients [J].
Yang, Zhe ;
Yang, Nong ;
Ou, Qiuxiang ;
Xiang, Yi ;
Jiang, Tao ;
Wu, Xue ;
Bao, Hua ;
Tong, Xiaoling ;
Wang, Xiaonan ;
Shao, Yang W. ;
Liu, Yunpeng ;
Wang, Yan ;
Zhou, Caicun .
CLINICAL CANCER RESEARCH, 2018, 24 (13) :3097-3107
[44]   EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer [J].
Shuhang Wang ;
Stella T. Tsui ;
Christina Liu ;
Yongping Song ;
Delong Liu .
Journal of Hematology & Oncology, 9
[45]   Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer [J].
Romanidou, Ourania ;
Landi, Lorenza ;
Cappuzzo, Federico ;
Califano, Raffaele .
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2016, 8 (03) :176-187
[46]   Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management [J].
Cooper, Alissa J. ;
Sequist, Lecia, V ;
Lin, Jessica J. .
NATURE REVIEWS CLINICAL ONCOLOGY, 2022, 19 (08) :499-514
[47]   ALK inhibitors in ALK-rearranged non-small cell lung cancer with and without brain metastases: systematic review and network meta-analysis [J].
Jiang, Jun ;
Zhao, Cong ;
Zhang, Fang ;
Liu, Zhenhua ;
Zhou, Kaiyuan ;
Ren, Xinling ;
Wan, Yi .
BMJ OPEN, 2022, 12 (09)
[48]   Brain metastases and mortality in patients with ALK plus metastatic non-small cell lung cancer treated with second-generation ALK tyrosine kinase inhibitors as first-line targeted therapies: An observational cohort study [J].
Uprety, Dipesh ;
Abrahami, Devin ;
Marcum, Zachary A. ;
Li, Benjamin ;
Sang, Angela ;
Davis, Matthew ;
Rifi, Nada ;
Kelton, John M. ;
Ramaswamy, Krishnan ;
Sanghvi, Parag ;
Bazhenova, Lyudmila .
LUNG CANCER, 2025, 201
[49]   BRAF inhibitors in metastatic non-small cell lung cancer [J].
Anguera, Georgia ;
Majem, Margarita .
JOURNAL OF THORACIC DISEASE, 2018, 10 (02) :589-592
[50]   ALK-based dual inhibitors: Focus on recent development for non-small cell lung cancer therapy [J].
Liu, Qiu-Ge ;
Wu, Ji ;
Wang, Zi-Yue ;
Chen, Bing-Bing ;
Du, Yi-Fei ;
Niu, Jin-Bo ;
Song, Jian ;
Zhang, Sai-Yang .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2025, 291
12345